KalVista Pharmaceuticals(KALV) - 2025 Q2 - Quarterly Results

Financial Performance - KalVista reported no revenue for the three months ended October 31, 2024, and the same period in 2023[9]. - The net loss for the three months ended October 31, 2024, was $42.3 million, compared to a net loss of $27.7 million for the same period in 2023[21]. - The weighted average common shares outstanding for the three months ended October 31, 2024, was approximately 46.7 million[21]. Expenses - Research and development expenses decreased to $16.6 million for the three months ended October 31, 2024, from $19.1 million in the prior year, a reduction of approximately 13.1%[9]. - General and administrative expenses increased significantly to $29.2 million for the three months ended October 31, 2024, compared to $10.7 million in the same period last year, an increase of approximately 172.0%[10]. Cash Position - As of October 31, 2024, KalVista had cash, cash equivalents, and marketable securities of approximately $135.8 million, with a pro forma balance of $292.2 million expected to provide runway into the second half of 2027[10]. - The company raised a total of $160 million through synthetic royalty financing and equity offerings in November 2024[8]. Regulatory and Market Developments - The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of June 17, 2025, for the New Drug Application (NDA) of sebetralstat[3]. - KalVista has filed six marketing authorization applications for sebetralstat in various countries, with the first potential approval expected in June 2025[3]. - KalVista presented new data at multiple conferences, highlighting the effectiveness of sebetralstat in reducing anxiety during HAE attacks[7].